Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707211 | 1.00 | GAA (0.40) | GAATNFADORA1ADORA2AADORA2B | |
| SCHEMBL6352844 | 0.86 | ALDH1A1 (0.41) | GAAADORA1ADORA2AADORA2B | |
| SCHEMBL6348689 | 0.86 | ALDH1A1 (0.41) | GAAADORA1ADORA2AADORA2B | |
| SCHEMBL6348685 | 0.86 | ALDH1A1 (0.41) | GAAADORA1ADORA2AADORA2B | |
| SCHEMBL27604723 | 0.86 | PDE4A (0.39) | ADORA2A | |
| SCHEMBL27604724 | 0.86 | PDE4A (0.39) | ADORA2A | |
| SCHEMBL6355684 | 0.84 | PDE4A (0.41) | GAAADORA2A | |
| SCHEMBL6355685 | 0.84 | PDE4A (0.41) | GAAADORA2A | |
| SCHEMBL4707344 | 0.81 | ADORA1 (0.53) | GAAADORA1ADORA2AADORA2B | |
| SCHEMBL4707343 | 0.81 | ADORA1 (0.53) | GAAADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1690864-B1 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7247630-B2 | Uses of tricyclic compounds | CELL THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1690864-A2 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS, INC. (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1347976-A2 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBIOTRS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS, INC. (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030162801-A1 | Tricyclic compounds and their uses | GONG BAOQING (US) | 2003-08-28 | — | — | US | disclosed |
| US-6586429-B2 | For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders | CELL THERAPEUTICS, INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2002068421-A2 | TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING | CELL THERAPEUTICS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | CELL THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162801-A1 | Tricyclic compounds and their uses | NFATC1, MAVS, STAT3 | GAA 1350/4885TNF 109/4885ADORA1 4302/4885 |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | XDH, MAVS, TPX2 | GAA 1485/4885TNF 219/4885ADORA1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.